“Zombielike” Aggression in Perampanel Overdose

Rami Z. Morsi 1, Jeffrey A. Katz 2

1. Neurology, University of Chicago, Chicago, USA  2. Anesthesia, NorthShore University HealthSystem, Evanston, USA

Corresponding author: Rami Z. Morsi, ramimorsi95@gmail.com

Abstract

Perampanel is an antiepileptic drug that blocks amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors. To date, little is known about the management of perampanel intoxication. We report a case of “zombielike” behavior secondary to intentional perampanel overdose. An 18-year-old male with idiopathic generalized epilepsy and focal features presented with aggressive and "zombielike" behavior after suicide attempt via intentional perampanel overdose, amounting to approximately 128 mg. Clinical symptoms gradually improved with continuous dexmedetomidine infusion and intravenous lorazepam boluses five days after being admitted to the intensive care unit. While perampanel intoxication has been reported to be associated with central nervous system-related adverse effects, awareness of this association is necessary to prompt more appropriate management tailored to perampanel toxicity.

Introduction

Perampanel is the first antiepileptic drug in its class to be approved by the Food and Drug Administration for its adjunctive treatment in patients with epilepsy aged 12 years or older, more specifically in those with partial-onset seizures with or without secondary generalization [1]. Perampanel noncompetitively blocks amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors on post-synaptic neurons to reduce excitatory neurotransmission and spread of seizure activity [2,3].

While Phase III clinical studies demonstrate perampanel to be safe and well tolerated with continued effectiveness in improving seizure control, dose-dependent central nervous system (CNS) adverse effects have been reported. These dose-dependent treatment-emergent adverse events (TEAEs) include, but are not limited to, dizziness, fatigue, and somnolence [4]. In a pooled analysis of psychiatric and behavioral safety data conducted by Ettinger and colleagues, the most common dose-dependent TEAEs were irritability followed by aggression with overall rates of psychiatric TEAEs being higher in perampanel groups compared to placebo groups [5]. The FYDATA study conducted by Villanueva and colleagues found that patients treated with perampanel, particularly those with prior psychiatric comorbidities, such as hyperactivity and personality disorders, were more likely to experience adverse effects, such as dizziness, somnolence, and irritability, at 12 months [6]. Another study by Lee and colleagues demonstrated that pre-existing depression and a perampanel dose 8 mg daily were potential predictors for aggression. Interestingly, however, they also found that topiramate, when used in conjunction with perampanel, was protective against aggression in patients with focal epilepsy [7].

To date, little is known about the management of perampanel intoxication. Hoppner and colleagues report a suicide attempt of a 34-year-old female patient with symptomatic focal epilepsy due to tuberous sclerosis who ingested 204 mg of perampanel, which resulted in impaired consciousness and delirium, and was admitted for close monitoring [8]. Wu and colleagues also describe a case of a 40-year-old male patient with prior psychiatric comorbidities and no history of seizure disorder who ingested 60 mg of perampanel in a suicide attempt, resulting in severe aggression and was managed with haloperidol, lorazepam, and dexmedetomidine [9]. Here, we describe the clinical findings in a patient with history of idiopathic generalized epilepsy with focal features who ingested an estimated 128 mg of perampanel in a suicide attempt and presented with bizarre, aggressive, and “zombielike” behavior.

Case Presentation

The patient was an 18-year-old African American male with a history of idiopathic generalized epilepsy with focal features, history of medication noncompliance, no documented formal psychiatric comorbidities, history of substance use, and family history of seizures, who presented after suicide attempt via intentional overdose of perampanel. Patient started taking 8 mg of perampanel daily for 15 months prior to presentation. Patient had multiple trials of antiepileptic medications in the past, including levetiracetam, valproic acid, and lacosamide but patient continued to have breakthrough seizures despite dosage adjustments. On the day of presentation, after a psychosocial stressor provoking the patient to damage the house television, patient ingested his prescription of perampanel, estimated to be 128 mg, which was 16 times his daily dose. Patient was brought into the emergency department via emergency medical services...
perampanel overdose did not cause any significant changes in vital signs, such as blood pressure and heart rate. Additional sedation in the ICU setting was because of its ability to reduce the duration of delirium, agitation, and the need for mechanical ventilatory support. The patient's agitation was controlled with a continuous infusion of dexmedetomidine and haloperidol. This patient described his agitation using continuous infusions of dexmedetomidine and haloperidol. The patient described his agitation using continuous infusions of dexmedetomidine and haloperidol. The patient described his agitation using continuous infusions of dexmedetomidine and haloperidol.

The rationale behind the use of dexmedetomidine was because of its ability to reduce the duration of delirium, agitation, and the need for additional sedation in the ICU setting. Hoppner and colleagues also described a clinical scenario where a synthetic cannabinoid methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (AMB-FUBINACA) was associated with a "zombie" outbreak consisting of "zombielike" groaning, slow limb movement, blank staring at ceiling followed by severe agitation and violence toward self and others if any person was in close proximity. Overnight, patient received a total of four IV boluses of 0.5 mg of lorazepam after increased anger and aggression requiring three staff members to restrain patient for continued violent behavior including thrashing on his bed, kicking, punching, and biting staff members. One staff member had a severe bite wound that required medical intervention in the emergency department. Haloperidol was not initially given at the time for fear of interaction with perampanel, and dexmedetomidine was not given for lack of evidence regarding perampanel intoxication. During the first hospital day, patient was still extremely agitated after requiring a total of 11 mg of IV lorazepam and 5 mg of IV haloperidol throughout the day. His vital signs were within normal limits during this time, but patient had extreme liability between somnolence with blank staring at ceiling followed by severe agitation and violence toward self and others if any person was in close proximity.

On Day 2 of hospitalization, patient continued to display this labile behavior despite receiving a total of 10 mg of IV lorazepam boluses. Due to the lability of his behavior and the ineffectiveness of lorazepam, he was started on a continuous infusion of dexmedetomidine titrated to 0.9 mcg/kg/h combined with IV lorazepam boluses amounting to a total of 6 mg after further discussion with the poison control service. On Day 3 of hospitalization, patient's agitation was controlled with a continuous dexmedetomidine infusion at a rate of 0.7 mcg/kg/h combined with a total of 6 mg of IV lorazepam. On Day 4 of hospitalization, patient remained on continuous dexmedetomidine infusion at a rate of 0.6 mcg/kg/h combined with a total of 8 mg of IV lorazepam. Over the course of Day 5 of hospitalization, the continuous dexmedetomidine infusion was weaned off, and patient only required 2 mg of IV lorazepam. Patient was more awake, oriented, calm, and cooperative. Due to his improvement in mental status and no longer requiring sedation, patient was transferred out of the ICU. Patient did not require any additional sedative medications while on general medicine floors. His blood pressure was 138/83 mm Hg, heart rate was 81 beats/min, respiratory rate was 18 breaths/min, and SpO2 was 98% on room air. During his time on general medicine floors, repeat EKG showed a prolonged QTc of 460 milliseconds but patient continued to be well oriented, calm, and cooperative, and was transferred to psychiatric inpatient services voluntarily. Patient was started on 100 mg of zonisamide daily after discharge and gradually increased to 200 mg daily and has had no seizures or changes in mood or behavior since.

**Discussion**

To the best of our knowledge, this is the first case report of a patient with a documented epilepsy disorder presenting with severe agitation and aggression mimicking zombielike behavior after perampanel overdose who was treated with continuous dexmedetomidine infusion and IV boluses of lorazepam. In New York, synthetic cannabinoid methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (AMB-FUBINACA) was associated with a "zombie" outbreak consisting of "zombielike" groaning, slow limb movement, blank stares, and delayed response to questioning. This is the first case report illustrating "zombielike" behavior consisting of moaning, blank stares, erratic limb movement, grabbing, and biting actions associated with perampanel overdose. Revonsuo and colleagues highlight that "Zombiehood" implies automatic behaviors -- whether routine or nonroutine, such as open eyes in a "glazed" appearance, detachment from the environment, bizarre behaviors encompassing aggressive and defensive measures -- can be carried out, even in a state of impaired consciousness. Perampanel has been associated with several psychiatric adverse events as evidently described by Ettinger and colleagues, but there is no clear management plan for perampanel overdose. Wu and colleagues reported a case of a suicide attempt in an individual with prior psychiatric comorbidities but no documented epilepsy and were able to control the patient's agitation using continuous infusions of dexmedetomidine and haloperidol. This patient described by Wu and colleagues demonstrated improvement in mental status after four days of hospitalization, which was similar to the patient described in this report who needed nearly the same amount of days for the perampanel overdose to gradually clear out of the system. The rationale behind the use of dexmedetomidine was because of its ability to reduce the duration of delirium, agitation, and the need for additional sedation in the ICU setting. Hoppner and colleagues also described a clinical scenario where perampanel overdose did not cause any significant changes in vital signs, such as blood pressure and heart rate.
rate, which was similarly seen in the clinical scenario described in this report. However, no clear management plan was described by Hoppner and colleagues [8]. Parsons and colleagues described a case of a 20-year-old treatment-naive male patient with no prior medical problems who experienced prolonged unconsciousness as a result of a mixed overdose involving perampanel, levohydroxime, and pregabalin [13]. This patient required endotracheal intubation for airway protection, sedation with propofol and fentanyl, and general supportive care [13]. One case was reported by Kim and colleagues regarding a 59-year-old female with documented seizures who experienced altered consciousness after ingesting 40 mg of perampanel and 10,000 mg of valproic acid [14]. This female patient’s hospital stay was further complicated by pulmonary embolism requiring heparin anticoagulation and mechanical ventilation. However, no sedation measures were highlighted in this case study [14].

The long mean half-life of 105 hours and the dose-dependent CNS adverse effects associated with perampanel should be given extreme caution given the negative consequences this drug has on an individual’s mental status when consumed in supratherapeutic levels [15]. Gidal and colleagues demonstrate that while higher plasma concentrations of perampanel are inversely related to seizure frequency, higher perampanel plasma concentrations are, nevertheless, directly related to adverse effects [16]. While clinical trials have demonstrated that common adverse effects of perampanel include somnolence, fatigue, irritability, headache, dizziness, irritability, ataxia, dysarthria, and memory impairment, there have been increasing cases of suicidality related to perampanel intake [5,17]. Perampanel’s ability to penetrate the blood-brain barrier when ingested orally largely attributes to these CNS adverse effects [18]. It has also been hypothesized that perampanel’s AMPA antagonist properties can alter glutamate levels, and, subsequently, lead to aggressive behavior [19,20].

Conclusions
This case report highlights the need for additional data to understand the pharmacologic effects of perampanel on the CNS as well as uncover mechanisms for managing CNS-related adverse effects induced by perampanel. While continuous dexmedetomidine infusion and lorazepam boluses were considered in this patient’s clinical course, more information is needed to guide medical decisions given the scarcity of the literature on perampanel toxicity-related suicidality and aggression.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Krauss GL, Serratos JM, Villanueva V, et al.: Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012, 78:1408-15. 10.1212/WNL.0b013e318254473a
2. Rogawski MA, Hanada T: Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013, 19-24. 10.1111/ane.12100
3. Wu T, Nagaya Y, Hanada T: Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model. Seizure. 2014, 23:732-9. 10.1016/j.seizure.2014.06.001
4. French JA, Krauss GL, Steinhoff BJ, Sillilacote D, Yang H, Kumar D, Laurerzen A: Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2015, 54:117-25. 10.1111/epilepsyp.1328-1167.2012.05638.x
5. Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, Laurenz A: Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015, 56:1252-63. 10.1111/epi.13054
6. Villanueva V, Garcés M, López-González FJ, et al.: Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. Epilepsy Res. 2016, 126:201-10. 10.1016/j.eplepsres.2016.08.001
7. Lee SA, Jeon YJ, Kim HW: Effect of perampanel on aggression in patients with refractory focal epilepsy: a 6-month longitudinal study. Epilepsy Behav. 2020, 102:106658. 10.1016/j.yebeh.2019.106658
8. Hoppner AC, Fauser S, Kerling F: Clinical course of intoxication with the new anticonvulsant drug perampanel. Epileptic Disord. 2015, 15:15-23. 10.1016/j.esid.2015.0598
9. Wu CC, McShane M, Huttlin EA, Nova K: Severe aggression after perampanel overdose: case report. Psychosomatics. 2019, 60:521-4. 10.1016/j.pyrsym.2018.07.002
10. Adams AJ, Banister SD, Iriazry L, Trecki J, Schwartz M, Geronia R: ‘Zombie’ outbreak caused by the synthetic cannabionoid AMB-FUBINACA in New York. N Engl J Med. 2017, 376:335-42. 10.1056/NEJMoa1610500
11. Revonsuo A, Johansson M, Wedlund J, Chaplin J: Effect of perampanel on aggression in patients with refractory focal epilepsy: a 6-month longitudinal study. Epilepsia. 2013, 54:117-25. 10.1111/epilepsyp.1328-1167.2012.05638.x
12. Pasin L, Landoni G, Nardelli P, et al.: Dexmedetomidine reduces the risk of delirium, agitation and
confusion in critically ill patients: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2014, 28:1459-66. 10.1053/j.jvca.2014.03.010

13. Parsons G, Bailey J, Bailey F, Brzezicki M: Prolonged unconsciousness in perampanel overdose. BMJ Case Rep. 2019, 12:e232517. 10.1136/bcr-2019-232517

14. Kim S, Kim TE, Kim D, Kim DW: Prolonged stupor in perampanel overdose and pharmacokinetic considerations. J Epilepsy Res. 2018, 8:87-9. 10.14581/jer.18014

15. FYCOMPA US Prescribing Information. (2016). Accessed: April 30, 2021: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf.

16. Gidal BE, Ferry J, Majid O, Hussein Z: Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013, 54:1490-7. 10.1111/epi.12240

17. Steinhoff BI, Ben-Menachem E, Ryvlin P, et al.: Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013, 54:1481-9. 10.1111/epi.12212

18. Di L, Kerns EH: Blood-brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. John Wiley & Sons, Hoboken, NJ; 2015.

19. Araki R, Ago Y, Hasebe S, et al.: Involvement of prefrontal AMPA receptors in encounter stimulation-induced hyperactivity in isolation-reared mice. Int J Neuropsychopharmacol. 2014, 17:883-95. 10.1017/S1461145713001582

20. Vekovischeva OY, Aitta-aho T, Verbitskaya E, Sandnabba K, Korpi ER: Acute effects of AMPA-type glutamate receptor antagonists on intermale social behavior in two mouse lines bidirectionally selected for offensive aggression. Pharmacol Biochem Behav. 2007, 87:241-9. 10.1016/j.pbb.2007.04.020